Loading...
•
Dec 31, 2019
Innoviva Q4 2019 Earnings Report
Reported financial results for the fourth quarter ended December 31, 2019.
Key Takeaways
Innoviva's Q4 2019 results showed a decrease in RELVAR®/BREO® ELLIPTA® global net sales by 18% and a 2% decline in ANORO® ELLIPTA® global net sales. However, TRELEGY® ELLIPTA® global net sales were $221.4 million. Despite challenges, the company's full-year income from operations rose, cash resources increased, and debt levels declined.
RELVAR®/BREO® ELLIPTA® global net sales decreased 18% versus Q4 2018, with U.S. sales declining 42% and non-U.S. sales increasing 11%.
ANORO® ELLIPTA® global net sales declined 2% in Q4 2019, with U.S. sales declining 7% and non-U.S. sales growing 9%.
TRELEGY® ELLIPTA® global net sales were $221.4 million.
Innoviva's full-year income from operations rose, cash resources increased, and debt levels declined despite new generic entrants.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...